Flibanserin: Restoring Female Sexual Desire and Satisfaction
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 12 | $4.02 | $48.28 (0%) | 🛒 Add to cart |
| 24 | $3.81 | $96.56 $91.53 (5%) | 🛒 Add to cart |
| 36 | $3.52 | $144.84 $126.73 (13%) | 🛒 Add to cart |
| 60 | $3.42 | $241.40 $205.19 (15%) | 🛒 Add to cart |
| 88 | $3.02
Best per pill | $354.05 $265.54 (25%) | 🛒 Add to cart |
Synonyms | |||
Flibanserin, commonly referred to as “female viagra,” is a groundbreaking non-hormonal prescription medication specifically developed to address hypoactive sexual desire disorder (HSDD) in premenopausal women. This centrally acting agent works by modulating neurotransmitters in the brain to help restore balance and improve sexual motivation. Unlike treatments that focus solely on physiological aspects, flibanserin targets the neurochemical pathways associated with sexual interest, offering a clinically validated approach to managing this complex condition. Approved by regulatory authorities after extensive research, it represents a significant advancement in women’s sexual health therapeutics.
Features
- Active ingredient: Flibanserin 100mg
- Pharmaceutical class: Multifunctional serotonin receptor agonist and antagonist
- Administration: Oral tablet
- Packaging: Blister packs of 30 tablets
- Prescription status: Schedule-controlled medication
- Manufacturer compliance: Current Good Manufacturing Practice (cGMP)
- Stability: 24 months from manufacturing date
- Identification: Engraved with unique product code
Benefits
- Increases spontaneous sexual desire and reduces distress associated with low libido
- Enhances satisfying sexual events through improved sexual motivation
- Provides non-hormonal intervention for sexual dysfunction
- Addresses the neurochemical imbalance associated with HSDD
- Improves overall sexual satisfaction and intimacy
- Offers targeted action without affecting hormonal contraception
Common use
Flibanserin is specifically indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by persistently or recurrently deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The diagnosis requires that these symptoms not be better accounted for by another medical condition, substance use, or severe relationship distress. Clinical studies have demonstrated efficacy in women who experience distress due to their low sexual desire, with effects typically noticeable after 4-8 weeks of consistent use.
Dosage and direction
The recommended dosage is 100mg taken orally once daily at bedtime. Administration at bedtime is crucial due to the potential for dizziness, sleepiness, and fatigue. Tablets should be swallowed whole with water and not crushed or divided. Treatment should be initiated under physician supervision with regular follow-up assessments. Consistent daily dosing is essential for optimal therapeutic effect, as flibanserin requires steady-state concentration for efficacy. Dosage adjustment is not recommended for elderly patients or those with mild hepatic impairment, but contraindicated in moderate or severe hepatic impairment.
Precautions
Patients should be advised about the risk of hypotension and syncope, particularly in conjunction with alcohol consumption. Concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated. Caution is advised when prescribing to patients with low blood pressure or those taking antihypertensive medications. Women should use effective contraception during treatment as safety during pregnancy has not been established. Patients should avoid activities requiring complete alertness until they know how flibanserin affects them, particularly when first starting treatment or after dosage changes.
Contraindications
Flibanserin is contraindicated in patients with hepatic impairment, in combination with alcohol, and with concomitant use of moderate or strong CYP3A4 inhibitors. Additional contraindications include pregnancy, use in postmenopausal women, and use in men. Patients with a history of hypersensitivity to flibanserin or any component of the formulation should not use this medication. Concomitant use with other central nervous system depressants is not recommended due to additive sedative effects.
Possible side effects
Common adverse reactions include dizziness (11.4%), somnolence (11.2%), nausea (8.3%), fatigue (7.5%), insomnia (4.9%), and dry mouth (3.8%). Less frequent but serious side effects may include syncope (0.4%), hypotension (0.2%), and accidental injury (1.6%). Most side effects are dose-dependent and tend to decrease in frequency with continued treatment. Patients should report any persistent or severe side effects to their healthcare provider promptly.
Drug interaction
Flibanserin is primarily metabolized by CYP3A4 and CYP2C19 enzymes. Concomitant use with strong CYP3A4 inhibitors increases flibanserin exposure approximately 7-fold. Moderate CYP3A4 inhibitors increase exposure approximately 4-fold. Combined use with alcohol significantly increases the risk of severe hypotension and syncope. Interactions may occur with other CNS depressants, including benzodiazepines, narcotics, and sleep aids. Physicians should review all concomitant medications, including over-the-counter products and herbal supplements, before prescribing.
Missed dose
If a dose is missed, patients should skip that dose and take the next scheduled dose at the regular time. Doubling the dose to make up for a missed dose is not recommended due to increased risk of adverse effects. Patients should maintain their regular dosing schedule and contact their healthcare provider if multiple doses are missed or if they have questions about dosage management.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe dizziness, syncope, hypotension, and profound sedation. There is no specific antidote for flibanserin overdose. Treatment should consist of supportive measures, including monitoring of vital signs and ECG. Gastric lavage may be considered if performed soon after ingestion. Hemodialysis is unlikely to be effective due to high protein binding.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Flibanserin is available by prescription only and should be used under appropriate medical supervision. Individual results may vary, and not all patients will experience the described benefits. Patients should consult with a qualified healthcare professional for proper diagnosis and treatment recommendations based on their individual medical history and condition.
Reviews
Clinical trial data demonstrates that 53% of women treated with flibanserin reported meaningful improvements in sexual desire compared to 40% with placebo. Patients reported approximately 2.5 satisfying sexual events per month at baseline, increasing to 4.5 events monthly with treatment. In post-marketing surveillance, 68% of prescribing physicians report positive outcomes when patients adhere to treatment protocols and avoid contraindicated substances. Long-term studies show maintained efficacy with continuous use for up to 18 months.